Spirotriazoline oxindoles: A novel chemical scaffold with in vitro anticancer properties

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Drug Discovery

Background:

• Oxindole derivatives are recognized for their diverse biological activities.
• Spirocyclic compounds offer unique three-dimensional structures for drug design.
• Developing novel anticancer agents with improved selectivity is a critical need.

Purpose of the Study:

• To design and synthesize a novel library of spirotriazoline oxindoles.
• To evaluate the in vitro antiproliferative and cytotoxic effects of these compounds against various cancer cell lines.
• To investigate the molecular mechanisms underlying the anticancer activity of promising candidates.

Main Methods:

• Synthesis of twenty-six spirotriazoline oxindoles.
• In vitro antiproliferative assays using HCT-116 p53(+/+), HCT-116 p53(-/-), MCF-7, and MDA-MB-231 cancer cell lines.
• Cytotoxicity assessment against non-cancerous HEK 293T and CCD-18Co cell lines.
• Flow cytometry to analyze apoptosis and cell cycle progression.
• Western blotting to determine p53 and MDM2 protein levels.

Main Results:

• Four spirotriazoline oxindoles demonstrated selectivity against cancer cell lines compared to HEK 293T cells.
• Two compounds induced apoptosis and G0/G1 cell cycle arrest in HCT-116 cells, upregulating p53 and downregulating MDM2.
• Cytotoxic effects were observed in cancer cells but not in non-malignant CCD-18Co fibroblasts.
• Four compounds exhibited selectivity against MDA-MB-231 triple-negative breast cancer cells with IC50 values ranging from 3.5-6.7 μM.

Conclusions:

• Spirotriazoline oxindoles represent a promising class of anticancer agents.
• These compounds display selective cytotoxicity towards cancer cells, including aggressive triple-negative breast cancer.
• The observed mechanism involves apoptosis induction and cell cycle arrest, highlighting their therapeutic potential.